Deepak Nihalani is a Research Assistant Professor of Medicine in the Renal-Electrolyte and Hypertension Division at the University of Pennsylvania. He has a PhD in biotechnology and is an established laboratory investigator with strong interest in the field of protein structure, function and dynamics and particularly interested in the mechanisms that govern podocyte cytoskeletal architecture. His laboratory investigates the biology of the glomerular podocyte, a unique epithelial cell that appears to play a central role in most forms of glomerular disease. Diseases of the renal glomerulus that result in the nephrotic syndrome are important causes of morbidity and mortality. Injury to the kidney glomerulus is often characterized by heavy proteinurea associated with the loss of kidney filtration barrier commonly referred to as “slit diaphragm”. His research is aimed at understanding the regulation and function of proteins that are the critical components of this slit diaphragm. It has been hypothesized that the interactions mediated by several proteins including Nephrin and Neph1 are required for maintining the integrity of slit diaphragm. The focus of his research is to define the structures of these proteins and understand their spatial distribution at the slit diaphragm. His other interests are in defining the intracellular signaling pathways that are activated in response to activation of Nephrin and Neph1. For this purpose his lab uses a combination of biochemical, molecular biology and systems biology approaches. His lab also engages in the development of transgenic and knockout mouse models and zebrafish models that will be instrumental in examining the functional biology of podocyte proteins and their interactions.
Research Interest
Protein structure, function, dynamics and mechanisms that govern podocyte cytoskeletal architecture, Intracellular signaling pathways that are activated in response to activation of Nephrin and Neph1
Vivian Ellinger, after graduating in the Medical School of Universidade Federal Fluminense started teaching at Teresopolis Medical School. Returning to Rio de Janeiro, worked at the State Institute of Diabetes and Endocrinology, she is now Scientific Coordinator. She is also a Professor of medicine at the Medical School of the Universidade Severino Sombra.
She is an Active Member of the Endocrine Society and Board certified by the Brazilian Endocrinology and Metabolism Society.
She has been the President of the Diabetes department of the Brazilian Society of Endocrinology and Metabolism and re elected as President for the Regional Rio de Janeiro of the Brazilian Society of Endocrinology and Metabolism.
Over the past 30 years, she has authored numerous articles, book chapters, abstracts and presentations on Endocrinology and Metabolism.
Samuel Grossman is a Patient Aligned Care Pharmacist and an independent provider who provides medication management in the area of internal medicine for different disease states in the primary care clinic in the Manhattan VA. In addition, he is diabetes educator at the Department of Veterans Affairs New York Harbor Health Care System and provides diabetes management to patients in the clinic. He also serves as the President and clinical coordinator of Diabetes Care On-The-Go Inc., a diabetes consulting center that serves patients and healthcare professionals of New York (NY) and New Jersey (NJ). In promoting awareness for diabetes, he partnered with the Diabetes Foundation to coordinate several diabetes centers in urban communities across the state of NJ. He served as the Corporate Chair of the American Association of Diabetes Educators (AADE) New Jersey Coordinating. He is the recipient of the 2012 “Diabetes Educator of the Year” award from AADE New Jersey Coordinating body for work done to promote diabetes awareness in the community and the recipient of the 2013 “Specialty Pharmacist of the Year Award” awarded as part of the Next Generation Pharmacist award Program. He is a member of the Chronic Disease Advisory Board to the Commissioner of Health and Senior Services of the state of New Jersey. In addition, he is the Advocacy Chair and a member of the New Jersey Community Leadership Board for the American Diabetes Association.
Furthermore, he serves as an Adjunct Associate Professor at Hunter-Bellevue School of Nursing of the City University of New York, Clinical Assistant Professor of Pharmacy at Arnold & Marie Schwartz College of Pharmacy of Long Island University, and Adjunct Faculty at Skaggs School of Pharmacy of the University of Colorado. He has published numerous publications in the area of diabetes and has given many presentations nationwide about this topic.
Research Interest
Clinical outcomes following educational intervention
Non communicable diseases and its relation with patients’ lifestyle modification
Improved safety profile with medication therapy for patients with diabetes
Obesity / under nutrition paradox
Food and Nutrition Public policies with actions for prevention of diabetes and chronic diseases in urban areas
Larry K Ellingson
National Diabetes Volunteer Leadership Council
USA
Larry K. Ellingson, Fountain Hills, Arizona, holds a BS, Pharmacy, from North Dakota State University (NDSU), Fargo, North Dakota and an Executive MBA from Babson College, BabsonPark, Massachusetts.
He retired from EliLilly and Company in May 2001 after having been involved as a leader of global diabetes for Lilly for more than half of his career. He has held several other positions at Lilly including Director of Pharmaceutical New Product Planning for gastrointestinal, skeletal, endocrine and infectious diseases, along with responsibility for marketed products in those areas in the late 1980’s.
He continues to remain active with committee work and board positions for a multitude of organizations. Among them are NDSU, Research Park, International Diabetes Federation, Academy of Nutrition and Dietetics, Nurse Practitioners Healthcare Foundation and the American Diabetes Association®. His contributions to the Association have been abundant and far-‐reaching and have spanned over 20 years. He has held numerous positions within the Association such as member of the Industry Advisory, Strategic Marketing Task Force, Strategic Planning Task Force, Big Ticket Task Force, Pinnacle Society and most recently, the Income Development Committee. He has been Chair or Vice Chair for an equally extensive list of bodies within the Association including the Board of Directors, Fundraising Committee, Executive Committee and Nominating Committee. He has unquestionably been a positive force and integral to mission delivery.
He has been honored several times for his achievements in his field. He was honored by being the first and only non–scientist to receive Eli Lilly’s President’s Award and the Lilly Research Award for contributions to diabetes research. In 2001, Eli Lilly created the Ellingson Legacy Award to honor those who provide outstanding service to the customer and Ellingson, Himself, was the first recipient. The ADA, Indiana affiliate awarded Larry the J.K. Lilly Award in 2004 for his contributions & service to the field of diabetes. NDSU awarded him the highest honor in 2007, naming him An Outstanding Alumni of the Year for his contributions to the field and to the University. The American Diabetes Association® recognized Larry in 2006 with the Charles H. Best Medal for Outstanding Service for his exceptional contributions as Chair of the Board.
Dhiren Patel serves as an Associate Professor at the Alpert Medical School of Brown University and at Massachusetts College of Pharmacy & Health Sciences (MCPHS) in Boston. He also works as a Clinical Pharmacy Specialist at the Boston VA where he functions at the highest level of clinical practice as a mid-level provider to initiate, modify or discontinue medication therapy for a variety of disease states such as diabetes, hypertension and dyslipidemia.
He has also served as a consultant pharmacist to a variety of clients that include, but not limited to the federal government, global biopharmaceutical companies, Fortune 500 firms, and healthcare technology startup companies. He has been published in peer-reviewed pharmacy journals and delivered numerous presentations and lectures on a variety of pharmacy topics. He is also board certified as an ambulatory care pharmacist (BCACP), diabetes educator (CDE), and in advanced diabetes management (BC-ADM). He earned his PharmD from MCPHS - Boston and received his postdoctoral residency training at the VA Boston Healthcare System.
Anutosh Chakraborty did his PhD at the Indian Institute of Chemical Biology, Kolkata, India. As a graduate student, he worked on the impacts of protein-protein interactions in regulating protein aggregation. He discovered that adenosine kinase, which maintains the cellular AMP pool, forms soluble inactive aggregates in the cells. The chaperone, cyclophilin reactivates adenosine kinase by binding mediated disaggregation of the enzyme.
He did his postdoctoral research in the laboratory of Professor Solomon Snyder at the Johns Hopkins University School of Medicine, Baltimore, MD. As a postdoctoral fellow, he discovered that IP6 kinases (IP6K), the inositol pyrophosphate biosynthetic enzymes, regulate cell survival and metabolism. He demonstrated that deletion of the major IP6K, IP6K1, protects mice from age and high fat diet induced weight gain and insulin resistance. Thus, IP6K1 may emerge as a novel target in obesity.
Currently, he is an Assistant Professor in the department of Metabolism and Aging at The Scripps Research Institute, Florida. He continued to focus on the role and regulation of IP6K1 in energy homeostasis utilizing whole-body and tissue-specific IP6K1 knockout mouse models. In collaboration, he also works on development of potent IP6K inhibitors to treat obesity associated metabolic complications.
Research Interest
Anutosh Chakraborty have extensive experience in Genetic, Pharmacologic, Cell biological and Biochemical approaches to identify novel functions of biomolecules with implications in various diseases such as Obesity, Diabetes, Psychiatric disorders and Cancer. He discovered novel cellular function or regulation of kinases and chaperones like, inositol hexakisphosphate kinases (IP6Ks), adenosine kinase, Akt, CK2, GSK3, cyclophilin and HSP90. The long term research interest of the laboratory is to discover novel targetable biomolecules to treat metabolic diseases.
Masayoshi Yamaguchi is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-Present). Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013).
He is engaged in the fields of bone and calcium endocrinology and cell calcium signaling since 1971. Moreover, his discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001) in mammalian cells. He generated regucalcin transgenic rats, which were registered as international patents (USA, EU, Japan and Korea) and this animal is found to induce osteoporosis and hyperlipidemia. Recently, he proposes that regucalcin is a target molecule in carcinogenesis of various cancer cell types. Currently, the research of regucalcin is focused as a scientific topic. He published over 500 English articles to professional journals with peer-review. In addition, he registered over 20 national and international patents in the fields of his research interesting.
He is serving as editors and editorial board members of reputed 40 international Journals. He received many honor and awards. He is listed in various biographies; Who’s Who in the World (2005-, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004-, Marquis Who’s Who, USA), International Biographical Dictionary (2006-, IBC, England) and others.
Research Interest
His researches are developed in the aspect of Biochemistry, Molecular biology, Endocrinology, Metabolism, Nutrition, Pharmacology and Toxicology. He has an interesting for Cell signaling mechanism, Bone biology, Nutritional factor and Osteoporosis prevention, Diabetic osteoporosis, and Cancer bone metastasis and Osteolysis.
Sunil Wimalawansa is a former university professor, Professor of Medicine, Chief of Endocrinology, Metabolism & Nutrition, world-renowned expert in endocrinology; osteoporosis and metabolic bone disease, and vitamin D and nutrition. He holds numerous distinctions as an educator, author, researcher, innovator, executive board member, an administrator, and philanthropist, and several academic credentials, including an MD, PhD, MBA, DSc, and several other postgraduate degrees. His contributions to medicine include development of once-a-week bisphosphonate therapy, combination therapies for osteoporosis, technique to enhance efficacy of bisphosphonates, and cost-effective therapies such as vitamin E and nitric oxide donor regimens for osteoporosis. In 1984, he pioneered the intra-operative hormone assays using measurements of calcitonin and parathyroid hormones as examples to assist endocrine surgical procedures. He is a multiple award-winner, including young investigator awards from several professional societies, Dr. Boy Frame Award for Clinical Excellence in Metabolic Bone Diseases, American Endocrine Society Glen Foundation Awards, and an innovation award from the Asian Chamber of Commerce. He received a coveted Lifetime Achievement Award for his contributions to science, humanity and society. The ISCD recognized his humanitarian contributions by awarding him the 2007 Dr. Oscar Gluck Humanitarian Award.He had served on several national and international scientific review committees [Click], including the NIH, VA, DEA and NASA. Current affiliation: Cardio-Metabolic Institute of New Jersey, U.S.A
Research Interest
Osteoporosis and metabolic bone diseases, Bone mineral density/DXA, Vitamin D, Nutrition, Micronutrients, Obesity, Type 2 diabetes, General Endocrinology.
Raghu Mirmira received his bachelor’s, MD and PhD degrees from the University of Chicago. During his PhD training, he worked under Howard Tager studying insulin-receptor interactions. After completion of his MD/PhD degrees, he subsequently completed his residency in Internal Medicine and subspecialty training in Diabetes and Endocrinology at the University of California at San Francisco. During his fellowship, he did his research training in the laboratory of Michael German, where he studied transcriptional regulation by Nkx6.1 in the β cell. During this time, he held the prestigious Physician Postdoctoral Fellowship Award from the Howard Hughes Medical Institute, a JDRF Career Development Award and later a Research Career Award from the National Institutes of Health. He then joined the faculty at the University of Virginia in 2000, where he studied several transcription factors that direct the development and function of beta cells, including Nkx6.1 and Pdx1. He then moved to Indiana University in 2008 to assume directorship of the burgeoning Diabetes Center. He is currently the Eli Lilly Professor in Pediatric Diabetes and Director of the Diabetes Center at Indiana University in Indianapolis and also Director of the MD/PhD (MSTP) program at IU School of Medicine. He is a Professor in the Departments of Pediatrics, Medicine, Cellular and Integrative Physiology, and Biochemistry and Molecular Biology. He has a research lab of 10 scientists. He continues to take care of patients with diabetes in clinic, teaches in the School of Medicine, and is Associate Editor of Molecular Endocrinology ad the Journal of Diabetes and its Complications. His lab is funded by the NIH, JDRF, and ADA. He is a member of the American Society for Clinical Investigation.
Research Interest
His research has more recently focused on mechanisms by which inflammation affects the islet β cell in type 1 diabetes mellitus.
Michael McDermott
University of Colorado Denver School of Medicine
USA
Michael McDermott is Professor of Medicine and Clinical Pharmacy at the University of Colorado Denver Health Sciences Center and is the Director of the Endocrinology and Diabetes Practice at the University of Colorado Hospital. He is board certified in Internal Medicine and in Endocrinology, Metabolism and Diabetes. He graduated from the Georgia Institute of Technology in 1974 with a BS in Chemistry and obtained his medical degree from Tulane Medical School in 1977. He did his Internal Medicine Internship and Residency from 1977-1980, and his Endocrinology and Metabolism Fellowship from 1980-1982, all at Fitzsimons Army Medical Center in Aurora, Colorado. He spent 20 years in the US Army during which he was the Chief of Endocrinology at Fitzsimons Army Medical Center from 1993-1997 and he served as the Endocrinology Consultant to the Surgeon General from 1994-1997. He retired from the US Army in 1997 and joined the faculty at the University of Colorado. He is a Fellow of the American College of Physicians and is a member of The Endocrine Society, The American Diabetes Association, The American Society for Bone and Mineral Research and The American Thyroid Association. His primary research interests include novel approaches to the management of Type 1 and Type 2 Diabetes Mellitus.
Margery A Connellyis Vice President of Translational Research at LabCorp and Adjunct Professor in the Molecular Medicine Department at Wake Forest School of Medicine. She earned her Ph.D. in Pathology and Immunology from Stony Brook University School of Medicine and is a Fellow of the American Heart Association. She was a Research Assistant Professor in the Department of Pharmacological Sciences at Stony Brook University for several years where her research focus was lipoprotein metabolism and inflammation.
In 2004, she accepted a position at Janssen Research & Development (Johnson & Johnson’s pharmaceutical division) where she applied her expertise in pharmacology, atherosclerosis and lipid metabolism to drug discovery. While at Janssen she was promoted to Principal Scientist and Atherosclerosis Group Leader and eventually led the Cellular and Biochemical Pharmacology Section of the Metabolic Discovery team. As part of her leadership development, she earned her MBA in Pharmaceutical Management at Drexel’s LeBow College of Business. She played a key role in building collaborative relationships with academic laboratories and biotech companies in order to expand Janssen’s discovery research capabilities. Before leaving Janssen, she was promoted to Scientific Director and received the title of Janssen Fellow in recognition of her global scientific accomplishments. In 2013 she joined LipoScience, a diagnostic company in NC, which is now part of LabCorp. In her current role as VP of Translational Research, she has been applying her scientific expertise and leadership toward the development of new NMR-based in vitro diagnostics for diagnosis and prognosis of various diseases.
Research Interest
Diabetes, Cardiovascular disease, Obesity, Inflammation, Therapeutics, Diagnostics and Personalized medicine
Benjamin U Nwosu is an Associate Professor of Pediatrics and Endocrinology at the University of Massachusetts Medical School in Worcester. He received his medical degree from the College of Medicine, University of Nigeria. He completed his residency training in Pediatrics and Child Health at the Howard University Hospital in Washington DC, and obtained his fellowship training in Pediatric Endocrinology at the National Institutes of Health, in Bethesda, Maryland, USA.
Research Interest
His research focus is on Childhood obesity, Vitamin D physiology and Diabetes. He is the principal investigator on a randomized, double-blind, placebo-controlled trial on the effects of adjunctive metformin therapy on glycemic control in children and adolescents with double diabetes.
Paul Burn is a successful senior scientist with a lifelong mission, focus and passion of improving the human condition by delivering products, cures and care to patients and their families. As a senior executive with extensive global industry and international management experience, he has a proven track record of success in Academia, Pharmaceutical R&D, Biotech, Not-for-Profit and Integrated Health Care organizations. He implemented multiple patient-centric approaches which resulted in successful basic and translational research and development programs, in the pharmaceutical, nutrition, diagnostic, personalized medicine, treatment and cure areas.
With over 30 years of experience in pharmaceutical and nutritional R&D and academia, he spearheaded many programs, from the gene to the clinics and through marketed products in the Endocrine, Metabolic, Cardiovascular, Renal, Bone, Musculoskeletal, Inflammation, Autoimmunity, Neuroscience, Dermatology, Oncology and Women’s Health therapeutic areas. Under his leadership multiple programs resulted in the successful identification of clinical candidate molecules, their evaluation in humans and subsequent market introduction.
Most recently he served as Chair and Director at Sanford Health, the largest rural health care provider in the US and as Professor of Pediatrics at the Sanford School of Medicine of The University of South Dakota. He also serves on several Boards and Scientific Advisory Boards of Universities, Biotech companies and Government agencies.
Prior to joining Sanford Health and the Sanford School of Medicine, he gained extensive international leadership and R&D experience in the Pharmaceutical and Biotech industry, in Academia and in Not-for-Profit and Health Care organizations. He served in the position of Senior Vice President of Research & Development at the Juvenile Diabetes Research Foundation (JDRF); at Hoffman-La Roche as the Global Head for the Metabolic Diseases Therapeutic Area and as Vice President of Biotechnology; at Eli Lilly & Company where he performed as the Director of Endocrine Research & Clinical Investigation; as Vice President of Research & Development for the Nutrition division at Monsanto/Pharmacia; and as Director of Metabolic Disease Research & Development at Bayer Health Care.
Previously, he held positions at various academic institutions, including the University of California, San Diego, CA and the University of Basel, Switzerland. He authored more than a hundred articles in some of the most prestigious scientific journals.
Research Interest
Metabolic Diseases, Endocrinology, Metabolic Disorders, Metabolic Control, Metabolic Fitness, Cardiovascular Diseases, Renal Diseases, Bone Diseases, Musculoskeletal Diseases, Inflammatory Diseases, Autoimmune Diseases, Pediatric Diseases, Nutrition, Type 2 Diabetes, Type 1 Diabetes, Obesity, Regeneration, Drug Discovery and Development, Translational Research, Clinical Research, Personalized Medicine.
Solomon Tesfaye
Sheffield Teaching Hospitals NHS Foundation Trust
USA
Robert J Chilton is Professor of medicine and Director of the Cardiac Catheterization Laboratory at the University of Texas Health Science Center at San Antonio.
He is a fellow of the American College of Cardiology, American College of Physicians, American College of Osteopathic Internists and American Heart Association. He has chaired the Electrophysiology Board Examination for the American Osteopathic Association in addition to Interventional Board of Examiners.
Over the past 20 years, he has authored numerous articles, book chapters, abstracts and presentations on Cardiology. He has developed educational materials and has lectured widely, garnering several awards for his academic contributions, including 1994 Outstanding Teacher from the University of Texas Health Science Center at San Antonio, researcher of the year ACOI. He is Associate Editor for Catheterization and Cardiovascular Interventions, Clinical Diabetes and is on the Editorial Board of Diabetes Care, American Journal of Cardiology and others.
He received his residency at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma and a cardiology fellowship at the Wilford Hall United States Air Force Medical Center, San Antonio, Texas. He is Board certified in internal medicine, cardiovascular disease and electrophysiology.
Research Interest
Cardiovascular disease, Diabetes, Vascular biology, Proteomics and Translational biology.
John Clapham gained his degrees and PhD from Birkbeck College, University of London and has worked in the pharmaceutical industry for over 30 years.
He started his career as a scientist with Beecham Pharmaceuticals (now GSK) and joined the Avandia project team in 1994. From 2001 he joined AstraZeneca, first in Sweden then the UK. At AstraZeneca he was Senior Director of Bioscience providing project support, resource and strategy to the cardio metabolic, in particular diabetes, disease areas.
He has extensive experience of project management, capability and technology development, line management and people development. He has held senior leadership roles in both operational and disease area strategy teams.
Research Interest
· Drug discovery in diabetes, obesity and cardiovascular disease.
· Appetite.
· Energy expenditure.
· Drug treatment of diabetes.
· Pharmacology.
Kamran Mahmood Ahmed Aziz
Aseer Diabetes Center of Aseer Central Hospital
Saudi Arabia
Kamran M.A. Aziz completed his medical graduation at Jinnah Sindh Medical University (Sind Medical College) in 1998, and post-graduation in diabetic medicine at Baqai Institute of Diabetes and Endocrinology, Baqai University Hospital in 2003 (Karachi, Pakistan). He is a Professional Clinical Diabetologist, Diabetes Principal Research Scientist and Diabetes Investigator, currently working in Aseer Diabetes Center of Aseer Central Hospital, Ministry of Health, Saudi Arabia.
Dr.Kamran has a vast experience in hospital and clinical teaching in diabetic medicine and has delivered more than 600 lectures in international diabetes conferences, seminars, workshops and clinical training programs. He has trained more than 1000 undergraduates and postgraduates as diabetologist using his case presentations and problem based clinical learning methods. He has also been invited as speaker in international conferences / congress and also has been invited by multinational pharmaceutical companies to present his published research on different diabetic medications.
Dr.Kamran has been involved extensively in clinical research since 2000 and has authored several publications in internationally reputed and peer-reviewed scientific journals.
He is serving as editor and editorial board member / Advisor of more than reputed 30 international Journals. He is also an expert Statistical Advisor, and Reviewer and advisor for various international journals like Centers for Disease Control and Prevention (CDC) and Preventing Chronic Diseases (PCD), Government of USA; ElSEVIER Journals (Lancet, Diabetes Research and Clinical Practice, an IDF journal, Advances en Diabetología, Nephrology, The American Journal of Medicine ; American Journal of Cardiology);Bentham Science Publishers (USA); Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy (New Zealand); Bio Med Central Research Journals (United Kingdom) and others diabetes and scientific research journals as well. He has also authored and written chapter "Functional and Healthy Foods for the prevention and Management of Metabolic Syndrome and Diabetes" for the international textbook ""Introduction to Functional Food Science – textbook, 1st Ed (2013)" (Available on www.Amazon.com).
Research Interest
Neuropathy, Diabetic foot, Dyslipidemia, Nephropathy, HbA1c, Insulin secretion/Augmentation estimation in type-2 diabetics at clinical, Pathological and Molecular levels. His researches also focus on Diabetics with Hypothyroidism and its associated complications. He has done research also on oral agents such as metformin, GLP-1/incretin based therapies (DPP-4 inhibitors), oral hypoglycemic agents, and various insulins as well.
Pedro Miguel Pereira de Sousa Marques is a young Endocrinologist currently at Portuguese Institute of Oncology, Lisbon, Portugal. He is a member of relevant National and International societies: Portuguese Society of Endocrinology (Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo, SPEDM), Portuguese Study Group of Adrenal Tumors from the SPEDM, European Society of Endocrinology and The Endocrine Society. He has completed some courses and specific stages in Diabetology and Endocrinology areas. He gave several presentations at National and International level. He also conducted some works in different Endocrine areas, mostly in the Oncological field. He has some National and International publications completed. He is collaborating as peer-reviewer for International Medical Journals.
Research Interest
Gestational and pre-gestational diabetes, secondary diabetes (corticosteroid induced or after pancreatic surgeries), type 2 diabetes, and metabolic abnormalities in Polycystic Ovarian Syndrome. In endocrine oncology his main research areas are Thyroid Cancer, Neuro Endocrine Tumors and Pituitary Tumors.
Arturo Zarate was born in Mexico City and continued his education at the Medical School of San Luis Potosi, Mexico, followed by a residency in Internal Medicine and Endocrinology at Hospital of Nutritional disorders. He completed a research fellowship in gynecologic endocrinology at the Medical College of Georgia, Augusta GA and then another research fellowship at the Southwestern Foundation in San Antonio TX and finally at the University of California in Torrance. He received his doctorate in Medical Sciences from the National University of Mexico. At his return to Mexico, he became Professor and Chairman of the Department of Endocrinology, then Director of National Research Program in the Instituto Mexicano Seguro Social.
He has published over 400 scientific papers in various medical and scientific journals as well as seventeen chapters in book chapters. He was a friend and close collaborator of the pioneer medical studies with Nobel Laureate Andrew V. Schally using the hypothalamic hypophysiotropic hormones. As a physician scientist, was a pioneer in Clinical Neuroendocrinology, Women endocrinology, and Metabolic disorders. He has obtained a great deal of recognition from his peers and invited to deliver lectures in various countries. He also has been considered mentor and teacher of many endocrinologists.
He is Member of the Mexican Academy of Medicine, Mexican Academy of Sciences, Endocrine Society and Society for Gynecologic Investigation, Mexican Society of Endocrinology as well as Honorary Member of several international scientific societies. He has received distinguished Achievement Awards by the Mexican Public Health Ministry, the Mexican Endocrine Society and the National Academy of Medicine.
At present, he is Emeritus Investigator Research of Mexico and Emeritus Research at the Instituto Mexicano del Seguro Social. His present position is the Chair at the Endocrine Research Unit and Emeritus Professor of Endocrinology at the National University of Mexico and Emeritus Member of National Investigators Council.
Research Interest
Clinical Neuroendocrinology, Women endocrinology, and Metabolic disorders
Katsunori Nonogaki is a specialist of Diabetes care and Internal medicine. He has obtained PhD in Endocrinology, Metabolism, and Diabetes. Then, he worked as a Post-doc Fellow at the University of California, San Francisco and the Scripps Research Institute, La Jolla. During this period, his research has mainly focused on “the role of the central nervous system in the regulation of hepatic glucose production”, “cytokines and lipid metabolism”, and “brain serotonin systems and energy homeostasis”. He found the novel evidence in the dissociated pathways of serotonin 5-HT2C receptor and leptin in the central regulation of appetite and obesity and proposed a novel physiological theory of “central dissociated regulation of feeding and autonomic neural circuits”. Current studies are to determine the physiological mechanisms and potential treatment for obesity, diabetes and their complications. He is also developing novel medical devices for hypertension and diabetes.
Research Interest
Serotonin network, GLP-1 network, Feeding regulation, Hepatic glucose and lipid metabolism, Medical device trials for obesity, diabetes and hypertension.
Louay Labban is currently a Professor of Nutrition and Dietetics at A’Sharqiyah University in Sultante of Oman. Before that he taught for 6 years at Kalamoon University in Syria. He taught several courses related to nutrition and dietetics. Also he served as vice dean of faculty of health sciences at the same university. His role included academic and administrative tasks. Before joining Kalamoon University, he taught several courses in American Universities and also worked for different pharmaceutical companies in the United States for many years and he was responsible for studying the effect of newly developed medication on the nutritional status of volunteered patients and he also studied the drug-nutrient interaction for these medications. Nowadays, he is interested in studying the relationship between Vitamin D and chronic disease with more emphasis on type 2 Diabetes Mellitus and the nutritional management of it.
He has published several papers in peer-reviewed papers regarding nutritional intervention in Diabetes Mellitus management. He received his Bachelor degree from Damascus University in Syria, his Master degree from University of Newcastle upon Tyne in England and his doctorate degree fro La Salle University in the United States.
Research Interest
He is interested in exploring the medicinal value of some herbs such as Rosemary, Turmeric and Ziziphus Jujuba to treat some health problems such as glucose level, lipid profile (Hyper Cholesterolemia) and to change body size and composition. The effect of physical activity is also one of his research interests. He likes to work more on the effect of vitamin D supplementation on insulin secretion in type 2 diabetics.
Antonio Brunetti is a Professor in Endocrinology and Metabolism at the Department of Health Sciences, University “Magna Graecia” of Catanzaro, Italy. He graduated in 1983 in Medicine with highest honors at the University of Catania, Italy. In 1986 he obtained his specialty in Endocrinology and Metabolism from the same University. In 1992 he received the PhD degree in “Endocrinology and Metabolic Sciences” from the University of Naples, Italy, while he was working at the Division of Diabetes and Endocrine Research, University of California San Francisco. Since 2008, he coordinates the PhD program in “Endocrine-Metabolic and Nutritional Sciences”, at the University “Magna Graecia” of Catanzaro.
Over the past 20 years, he has authored numerous articles, book chapters, abstracts and presentations on Endocrinology and Metabolism. Currently, he is Associate Editor forseveral journals in this area and has been Guest Editor of several related journal Special Issues. He is a member of the American Diabetes Association, the European Society of Endocrinology and a member of the Italian Society of Diabetes.
Research Interest
Pathophysiology of insulin action, Insulin receptor expression and insulin action, Molecular genetics of type 2 diabetes and severe insulin resistance syndromes, Insulin resistance and cancer.
Damir Boras currently serves as Medical Advisor for diabetes and obesity at Novo Nordisk Canada. Previously, he served as Medical Advisor at AstraZeneca and Organon. He has extensive experience in protocol writing, study and project management. He obtained his medical degree from the University Of Sarajevo Medical School, Bosnia and Herzegovina. He did his Internal Medicine residency at the University Clinical Center Sarajevo and is board certified in Internal Medicine.
Dr. Ivan Domuschiev is born 1961 in the town Panagiuriste. He graduated the German Language School “Bertold Brecht” in Pazardjik City with fully excellent marks and a medal. He graduated in 1986 the Medical Univercity in Plovdiv city with fully excellent marks as promotor of the course (speciality“medicine“). He defended a dissertation with a conference on the scientific degree” Philosophy Doctor in Medicine“(Ph.D.) in the field of the endocrinology (diabetology).
He was long time Assistant-Professor in internal diseases and endocrinology as well as he leaded clinical exercises in postgraduated teaching. He worked as Assistant-Professor at the Clinic of Endocrinology – Medical University in Plovdiv, Clinic of Endocrinology- Medical Institute- Central Clinical Base in Sofia, National Sport Academy in Sofia.
He has 82 scientific publications, whereof 8 scientific monographies, 1 practical handbook for diabetics, as well as great number of participations at scientific symposiums and congresses in Bulgaria and foreign countries. His scientific publications are in the field of endocrinology, diabetology, cardiology and other areas of the internal medicine, neurovegetology, phytotherapy and anti-aging medicine. He has own scientific investigations in the field of the heart rate variability (HRV) in patients with various diseases.
He specialized in the area of endocrinology and diabetology in Moscow by Acad., Prof. M.D.I. Dedov, in Germany and Vienna by the well-known endocrinologist Prof. Michael Roden. He specialized in Moscow iridology by Prof. Verlhover and non-contact massage by Juna. He finished a course „ Introducing in Good Clinical Practice“ - lecturer Sue Fiztpatrick from the Institute of Clinical Research, London, as well as other courses in endocrinology and internal diseases. He specialized health management.
He is a fellow of Bulgarian Society of Endocrinology, Bulgarian Association of Diabetology, German Society of Diabetology, Austrian Society of Diabetology and European Society of Antiaging Medicine (ESAAM). He works at the present time as an endocrinologist in II. Department of Internal Medicine at Hospital “St. Panteleimon” in Plovdiv City. He worked previously as an endocrinologist in Clinic “Medicus Alpha“ in Plovdiv city and he led the Direction „Ant-aging Medicine“ in the same clinic and in medical holding „United Medical Group“ for 4,5 years.
Marianella Herrera completed graduation from Medical School in Caracas Venezuela, at Universidad Central de Venezuela. She holds a Master Degree in Human Nutrition from Universidad Simon Bolivar (USB). She will graduate with honors next May 2014 from her Doctorate in Human Nutrition with emphasis in Public Policies from USB. She is an assistant professor and researcher at CENDES, Centro de Estudios Del Desarrollo at Universidad Central de Venezuela. Where she actually conducts several lines of research related to early nutrition, Social inequities, Non communicable diseases and food and nutrition public policies. She has been involved in Nutrition education, Primary patient care and consulting for 20 years. In 2010, she was the recipient of The Diabetes Research Award from Foundation Seguros Caracas, for the project: Identifying risk factors of future Diabetes in Venezuelan school age children. From January 2010, she became the President elect at Sociedad Científica Venezolana de Obesología (SCVO) until January 2013. Currently she is the Country Representative Chair (Elected) at American Overseas Dietetic Association. In November 2010, she obtained the AODA service award for her work as a chair of the first AODA Latin American Symposium in Caracas. She has been publishing her work in national and international publications. She was a co-author for the Public Health/ Community Nutrition/ Nutrition Care Process developed by the Academy of Nutrition and Dietetics (USA). Actually she is the PI of the first cohort study in pregnant women in Venezuela and the coordinator of the Venezuelan Health Observatory.
Research Interest
· Non communicable diseases and its relation with socioeconomic inequities
· Identification of future type 2 diabetes socioeconomic predictors in school age Venezuelan children
· Household food insecurity measurement
· Nutrition transition in developing countries and its relationship with the
· Obesity / under nutrition paradox
· Nutrition education interventions
· Food and Nutrition Public policies with actions for prevention of non communicable diseases within welfare programs
Mehmet Akif Buyukbese was received both MD & internal medicine residency degrees from Istanbul University where he started focusing on diabetes. Founded internal medicine department at KSU School of Medicine in Kahramanmaras and served as a head for 6 years. Board certified in internal Medicine. Several Diabetes management and Research experiences in the USA: Albert Einstein College of Medicine, Bronx, NY (2001), MD Anderson Cancer Center & University of TX Houston Diabetes and Endocrinology (2007) Indian Medical Health Center, Diabetes Outpatient Clinic, NIH, (Phoenix) (2008-2009). He was Worked as a postdoctoral research fellow in UK (2003) (Univ. of Leicester, Clinical Diabetes Research Centre) and Kronos Longevity Research Institute, Phoenix, Arizona, USA. Holds an ECFMG certificate (2008) Gave diabetes lectures in Gottingen University-Germany through ERASMUS Programme (2012). Members of International Diabetes Foundation (IDF), Board of Trustees of Turkish Diabetes Foundation, European Society of Cardiology, Turkish Society of Metabolic Syndrome and Internal Medicine Society of Turkey. Served for Southeastern Anatolia Diabetes Project for 6 years (2000-2006) and Kahramanmaras City Coordinator of ‘Presidency of Turkey Diabetes-Peer’ Project for 2 years (2011-2013) Carried on his diabetes patient and family medicine physician (gp) education programs as well as phase 3 and phase 4 diabetes drug clinical studies Currently, working as the medical director of dunya diabetes centers at Dunyagoz Hospital in Istanbul since from Jan 2014. He Has more than a 100 publications both in Turkish and English in internal medicine area mostly in diabetes. In the editorial board of Journal of Clinical Medicine, Research and reviewer of Science Alert, European Journal of General Medicine, Balkan Medical Journal (SCI-Exp), Diabetes Forum (Turkish), Diabetes Science and Endocrinology (Turkish), Glance at Diabetes (Turkish), Turkey Clinics Medical Science, Turkey Clinics Endocrinology, Dialogue in Endocrinology (Turkish).
Hamid Baradaran is an Associate professor in Clinical Epidemiology at the Endocrine Research Centre, Institute of Endocrinology and Metabolism affiliated to Iran University of Medical Sciences. He graduated in 1993 in Medicine from Tehran then obtained his PhD in Clinical Epidemiology from University of Glasgow, Scotland, UK in 2004. He is engaged in the field of epidemiology of diabetes and its complication, particularly in prediction models. He published over 100 English articles to professional journals with peer-review. He is serving as editors and editorial board members of reputed international Journals. He is currently acting an executive member of the National Diabetes Program in Iran.
Research Interest
Prevention of Diabetes; Diabetes Psychology; Clinical Trials; Modelling
Dr. Tayek currently serves as the Medical Director of Nutrition Day in the USA and he is a full time Professor of Medicine at Harbor-UCLA Medical Center. He received a Bachelors of Arts Degree from California State University at Fullerton. He received his Masters of Science Degree from Columbia University where he was active in screening physicians for hypercholesterolemia and their risk for heart disease. He received his medical degree from Wayne State University in Detroit Michigan. After an Internal Medicine residency at UCI Medical Center, he received his Clinical Nutrition Fellowship training at New England Deaconess Hospital and Harvard Medical School. He completed a second fellowship in Endocrinology and Metabolism at Harbor-UCLA Medical Center. He is board certified in Internal Medicine, Endocrinology and Metabolism and in Clinical Nutrition. He is a full time faculty member at the David Geffen School of Medicine at UCLA. As a full time faculty in the Division of Internal Medicine at the Harbor-UCLA Medical Center, he teaches Nurse Practioners, Medical Students, Residents, Endocrinology Fellows and Junior Faculty.
Research Interest
As a Professor of Medicine-In Residence, he enjoys teaching and interacting closely with the Internal Medicine Residents and the Endocrinology Fellows in training at Harbor-UCLA. He attends Inpatient Internal Medicine Service, Inpatient Endocrinology Consultation Service and maintains an active Internal Medicine and Endocrinology clinical practice within the managed care community at Harbor-UCLA Medical Center. His clinical interests include Normal and Abnormal Liver Physiology, Diabetes, Hyperlipidemia , Clinical Nutrition, Sepsis and many others areas of Endocrinology. He was been a Principle Investigator on an NIH study of patients with alcoholic hepatitis and cirrhosis (2005-8) and is currently a principle site Investigator on a NIH grant about alcoholic hepatitis). He is also done research in the field of diabetes mellitus and cardiovascular diseases. His earlier NIH funded research also included development of equations to make accurate measurements of liver glucose and amino acid metabolism (NIH K08) in normal humans, diabetics and patients with systemic diseases.
Claudia Gragnoli is an MD/PhD Endocrinologist who has been working in the genetics of maturity-onset diabetes of the young (MODY), type 2 diabetes (T2D) and associated phenotypes. She graduated in Medicine and Surgery and became an Endocrinologist at the University La Sapienza of Rome and obtained her PhD at the U. T or Vergata of Rome. She performed her research at University of Chicago as JDFI Fellow, at Mass General Hospital as a Rotary International Ambassador and NIH Training Fellow. As Instructor in Medicine at Harvard Medical School she taught/tutored Human Genetics of Complex Disorders, Endocrinology, and Chemistry and Cell Biology. As Assistant Professor in Medicine, Molecular & Cellular Physiology and Public Health Sciences at Penn State University College of Medicine, she continued her research and has been Faculty Committee member of the Penn State University PhD Inter College Graduate Degree Program in Physiology, Genetics, Biomedical Sciences Program, and of the MD/PhD Program. At Penn State she taught endocrinology, diabetes, and genetics of monogenic and complex disorders. She has been Adjunct Associate Professor in Biology at Temple University’s College of Science and Technology in Philadelphia. She is American Board Certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism. She is Associate Professor in Medicine at the University of Florida, Jacksonville and Adjunct Associate Professor in Public Health Sciences at Penn State University.
Research Interest
Genetics of monogenic diabetes; Type 2 diabetes; Obesity; Metabolic syndrome; Depression and Other mental disorders
Vasilios G Athyros is an Associate Professor in Internal medicine, Academic Head of Atherosclerosis, Obesity, Metabolic Syndrome, and Peripheral Arterial Disease Out-patient Clinics, Aristotle University, Hippocration Hospital, Thessaloniki, Greece. He was a Chairman ofthe Hellenic Atherosclerosis Society during 2010-2012 and Vice Chairman during 2008-2010. Currently, he is a Vice Chairman of the Greek Chapter of American Society of Angiology, Fellow of the European Society of Cardiology and American Society of Clinical and Laboratory Scientists. He served as an Advisor for Canadian Institutes of Health Research in 2006, Irish Health Research Board and also for Diabetes UK in 2007.
He is serving as Editor-in-Chief in The Open Hypertension Journal (Bentham), Associate Editor in Bio-Med Central Public Health Journal and Section Editor in The Open Atherosclerosis & Thrombosis Journal (UK). He has been honored as a member of the Editorial Board for Current Medical Research and Opinion (UK), Vascular Disease Prevention (UK) and The Open Cardiovascular Medicine Journal (UK). He is also an invited referee in 867 reviews and 147 peer-reviewed journals.
Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
